Literature DB >> 34934932

GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway.

Akihito Ishikita1,2, Shouji Matsushima1,2, Soichiro Ikeda1, Kosuke Okabe1, Ryohei Nishimura1,2, Tomonori Tadokoro1, Nobuyuki Enzan1,2, Taishi Yamamoto1,2, Masashi Sada1,2, Yoshitomo Tsutsui1,2, Ryo Miyake1,2, Masataka Ikeda1, Tomomi Ide3, Shintaro Kinugawa1,2, Hiroyuki Tsutsui1,2.   

Abstract

Molecular mechanisms mediating cardiac hypertrophy by glucose metabolism are incompletely understood. Hexosamine biosynthesis pathway (HBP), an accessory pathway of glycolysis, is known to be involved in the attachment of O-linked N-acetylglucosamine motif (O-GlcNAcylation) to proteins, a post-translational modification. We here demonstrate that glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2), a critical HBP enzyme, is a major isoform of GFAT in the heart and is increased in response to several hypertrophic stimuli, including isoproterenol (ISO). Knockdown of GFAT2 suppresses ISO-induced cardiomyocyte hypertrophy, accompanied by suppression of Akt O-GlcNAcylation and activation. Knockdown of GFAT2 does not affect anti-hypertrophic effect by Akt inhibition. Administration of glucosamine, a substrate of HBP, induces protein O-GlcNAcylation, Akt activation, and cardiomyocyte hypertrophy. In mice, 6-diazo-5-oxo-L-norleucine, an inhibitor of GFAT, attenuates ISO-induced protein O-GlcNAcylation, Akt activation, and cardiac hypertrophy. Our results demonstrate that GFAT2 mediates cardiomyocyte hypertrophy by HBP-O-GlcNAcylation-Akt pathway and could be a critical therapeutic target of cardiac hypertrophy.
© 2021 The Authors.

Entities:  

Keywords:  Cell biology; Classification Description: Cellular physiology; Molecular physiology

Year:  2021        PMID: 34934932      PMCID: PMC8661546          DOI: 10.1016/j.isci.2021.103517

Source DB:  PubMed          Journal:  iScience        ISSN: 2589-0042


  44 in total

1.  O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.

Authors:  Heberty T Facundo; Robert E Brainard; Lewis J Watson; Gladys A Ngoh; Tariq Hamid; Sumanth D Prabhu; Steven P Jones
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-09       Impact factor: 4.733

Review 2.  Myocardial substrate metabolism in the normal and failing heart.

Authors:  William C Stanley; Fabio A Recchia; Gary D Lopaschuk
Journal:  Physiol Rev       Date:  2005-07       Impact factor: 37.312

3.  Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.

Authors:  Scott A Yuzwa; Xiaoyang Shan; Matthew S Macauley; Thomas Clark; Yuliya Skorobogatko; Keith Vosseller; David J Vocadlo
Journal:  Nat Chem Biol       Date:  2012-02-26       Impact factor: 15.040

4.  Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance.

Authors:  S Marshall; V Bacote; R R Traxinger
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

5.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

6.  Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus.

Authors:  Jack M Heath; Yong Sun; Kaiyu Yuan; Wayne E Bradley; Silvio Litovsky; Louis J Dell'Italia; John C Chatham; Hui Wu; Yabing Chen
Journal:  Circ Res       Date:  2014-02-13       Impact factor: 17.367

7.  Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity.

Authors:  Tomonori Tadokoro; Masataka Ikeda; Tomomi Ide; Hiroko Deguchi; Soichiro Ikeda; Kosuke Okabe; Akihito Ishikita; Shouji Matsushima; Tomoko Koumura; Ken-Ichi Yamada; Hirotaka Imai; Hiroyuki Tsutsui
Journal:  JCI Insight       Date:  2020-05-07

8.  O-GlcNAc Transferase Promotes Compensated Cardiac Function and Protein Kinase A O-GlcNAcylation During Early and Established Pathological Hypertrophy From Pressure Overload.

Authors:  Wei-Zhong Zhu; Danny El-Nachef; Xiulan Yang; Dolena Ledee; Aaron K Olson
Journal:  J Am Heart Assoc       Date:  2019-06-04       Impact factor: 5.501

9.  Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma.

Authors:  Allison R Hanaford; Jesse Alt; Rana Rais; Sabrina Z Wang; Harpreet Kaur; Daniel L J Thorek; Charles G Eberhart; Barbara S Slusher; Allison M Martin; Eric H Raabe
Journal:  Transl Oncol       Date:  2019-07-21       Impact factor: 4.243

10.  Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.

Authors:  Rana Rais; Andrej Jančařík; Lukáš Tenora; Michael Nedelcovych; Jesse Alt; Judson Englert; Camilo Rojas; Anne Le; Amira Elgogary; Jessica Tan; Lenka Monincová; Kelly Pate; Robert Adams; Dana Ferraris; Jonathan Powell; Pavel Majer; Barbara S Slusher
Journal:  J Med Chem       Date:  2016-09-06       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.